Medexus Pharmaceuticals Inc. MDP

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 24, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated August 10, 2026 as directors through the next annual meeting. Shareholders also voted in favor of the appointment of PricewaterhouseCoopers LLP as the company's auditors and in favor of resolutions amending the...

Medexus Pharmaceuticals (TSE:MDP) reported higher first-quarter fiscal 2027 revenue and adjusted EBITDA, supported by continued growth for GRAFAPEX and a stronger contribution from IXINITY, while management maintained its full-year outlook for the recently launched transplant-conditioning product.

Strong quarterly performance driven by record Graphopex sales and strategic expansion into cell therapy.

Fiscal Q1 2027 includes product-level net revenue from GRAFAPEX™ (treosulfan) for Injection of $4.9 million relative to $3.2 million of GRAFAPEX personnel and infrastructure investmentsCommercial traction observed to date reinforces Medexus confidence in the growth trajectory of GRAFAPEXManagement to host conference call at 8:00 AM Eastern time on Tuesday, August 11, 2026Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 10, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF)

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - July 30, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Tuesday, August 11, 2026 to discuss Medexus's results for its first fiscal quarter ended June 30, 2026. Medexus expects to file its financial statements and MD&A after markets close on August 10, 2026.To participate in the call, please dial the following numbers:888-506-0062 (toll-free) for Canadian and U.S....

Despite a dip in annual revenue, Medexus Pharmaceuticals Inc (MEDXF) shows resilience with improved EBITDA and strategic expansions.

Management to host conference call at 8:00 AM Eastern time on Friday, June 26, 2026Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's fourth fiscal quarter and fiscal year ended March 31, 2026 (the company's fiscal Q4 2026 and fiscal year 2026). All dollar amounts in this news release are in US dollars unless specified...

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 16, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Friday, June 26, 2026 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March 31, 2026. Medexus expects to file its financial statements and MD&A after markets close on June 25, 2026.To participate in the call, please dial the following numbers:888-506-0062 (toll-free) for Canadian...

UM171 Cell Therapy is conditionally approved in Europe as Zemcelpro® (dorocubicel)Securing Canadian rights to a proprietary advanced clinical-stage product candidate developed in Canada adds to Medexus's medium-term product pipeline and helps build a North American allo-HSCT franchiseToronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 9, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the company has secured exclusive Canadian rights to...

Markets have responded positively to recent geopolitical developments, with major U.S. equity benchmarks reaching new record highs, despite ongoing tensions in the Persian Gulf. In this context, investors are increasingly focusing on economic and corporate fundamentals rather than short-term fluctuations. Although the term "penny stock" might seem outdated, these investments still hold potential for significant returns when they are based on solid financials and growth prospects. Let's...

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 15, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today provided an operational business update on the ongoing commercialization of GRAFAPEX™ (treosulfan) for Injection in the United States and on certain recent capital allocation and capital structure developments and announced company management's participation in two upcoming investor conferences. All dollar amounts in this news release are in US dollars unless...

As the Canadian market navigates a landscape where technology stocks are experiencing valuation adjustments due to AI-driven disruptions and increased capital spending, investors are re-evaluating their strategies. Amidst this backdrop, penny stocks—often associated with smaller or newer companies—offer intriguing opportunities for those looking beyond the established giants. While the term might seem outdated, these stocks continue to provide potential growth at lower price points when...

The Canadian market is experiencing a period of adjustment as investors reassess valuations, particularly in the technology sector, amid concerns about AI-driven disruptions and increased capital spending. In this context, penny stocks—often smaller or newer companies with solid financial foundations—can still present intriguing opportunities for those seeking value and growth. Despite their vintage name, these stocks can offer significant potential when backed by strong financials, making...

As the Canadian market navigates a landscape influenced by global tech repricing and AI-driven shifts, investors are increasingly seeking opportunities beyond traditional sectors. Penny stocks, though an older term, remain relevant as they represent smaller or emerging companies that can offer unique value propositions. By focusing on those with strong financial foundations and clear growth potential, investors may uncover promising opportunities in this often-overlooked segment of the market.

The Canadian market, like its global counterparts, is navigating a period of recalibration as investors reassess the valuation of tech stocks amid rapid advancements in AI technology. In this context, penny stocks—often representing smaller or emerging companies—continue to capture investor interest due to their potential for significant growth. By focusing on those with strong financial health and clear growth prospects, investors can uncover opportunities that might offer both stability and...

As the Canadian market navigates through a period of tech repricing driven by AI-related disruptions and capital spending, investors are reassessing their strategies across various sectors. While high-profile technology stocks face volatility, penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities for those willing to explore beyond the mainstream. Despite its dated connotations, the term 'penny stock' highlights potential hidden value in...